Clinical Trial Update: PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating PET-adapted first-line therapy with nivolumab for advanced Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Hodgkin Lymphoma, Hodgkin Disease | Phase 2 | Status: RECRUITING